126 related articles for article (PubMed ID: 18556439)
1. Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret.
Minthorn E; Mencken T; King AG; Shu A; Rominger D; Gontarek RR; Han C; Bambal R; Davis CB
Drug Metab Dispos; 2008 Sep; 36(9):1846-52. PubMed ID: 18556439
[TBL] [Abstract][Full Text] [Related]
2. Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats, and dogs.
Miraglia L; Pagliarusco S; Bordini E; Martinucci S; Pellegatti M
Drug Metab Dispos; 2010 Oct; 38(10):1876-91. PubMed ID: 20622044
[TBL] [Abstract][Full Text] [Related]
3. Tissue distribution and characterization of drug-related material in rats and dogs after repeated oral administration of casopitant.
Pagliarusco S; Martinucci S; Bordini E; Miraglia L; Cufari D; Ferrari L; Pellegatti M
Drug Metab Dispos; 2011 Feb; 39(2):283-93. PubMed ID: 20978104
[TBL] [Abstract][Full Text] [Related]
4. Disposition and metabolism of radiolabeled casopitant in humans.
Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
[TBL] [Abstract][Full Text] [Related]
5. Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Griffante C; Pizzi DA; Donati D; Mattioli M; Cimarosti Z; Guercio G; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
J Med Chem; 2011 Feb; 54(4):1071-9. PubMed ID: 21229983
[TBL] [Abstract][Full Text] [Related]
6. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
Johnson BM; Adams LM; Zhang K; Gainer SD; Kirby LC; Blum RA; Apseloff G; Morrison RA; Schutz RA; Lebowitz PF
J Clin Pharmacol; 2010 Aug; 50(8):951-9. PubMed ID: 20124517
[TBL] [Abstract][Full Text] [Related]
7. Determination of casopitant and its three major metabolites in dog and rat plasma by positive ion liquid chromatography/tandem mass spectrometry.
Ferrari L; Reami D; Michi M
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Nov; 878(29):2974-82. PubMed ID: 20870467
[TBL] [Abstract][Full Text] [Related]
8. Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
Motta P; Pons N; Pagliarusco S; Pellegatti M; Bonomo F
Drug Metab Dispos; 2011 Mar; 39(3):363-72. PubMed ID: 21149541
[TBL] [Abstract][Full Text] [Related]
9. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
Colizza K; Awad M; Kamel A
Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
[TBL] [Abstract][Full Text] [Related]
10. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
Kirby LC; Johnson BM; Adams LM; Eberwein DJ; Zhang K; Murray SC; Lates CD; Blum RA; Morris SR
J Clin Pharmacol; 2010 May; 50(5):566-75. PubMed ID: 20220045
[TBL] [Abstract][Full Text] [Related]
11. Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist 'CJ-17,493'.
Shishido Y; Wakabayashi H; Koike H; Ueno N; Nukui S; Yamagishi T; Murata Y; Naganeo F; Mizutani M; Shimada K; Fujiwara Y; Sakakibara A; Suga O; Kusano R; Ueda S; Kanai Y; Tsuchiya M; Satake K
Bioorg Med Chem; 2008 Aug; 16(15):7193-205. PubMed ID: 18640044
[TBL] [Abstract][Full Text] [Related]
12. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
Hale JJ; Mills SG; MacCoss M; Finke PE; Cascieri MA; Sadowski S; Ber E; Chicchi GG; Kurtz M; Metzger J; Eiermann G; Tsou NN; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; MacIntyre DE
J Med Chem; 1998 Nov; 41(23):4607-14. PubMed ID: 9804700
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic effect of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin-induced acute and delayed emesis in ferrets.
Furukawa TY; Nakayama H; Imazumi K; Yamakuni H; Takeshita K; Matsuo M; Manda T; Uchida W
Biol Pharm Bull; 2014; 37(2):232-8. PubMed ID: 24492720
[TBL] [Abstract][Full Text] [Related]
14. Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
Di Fabio R; Griffante C; Alvaro G; Pentassuglia G; Pizzi DA; Donati D; Rossi T; Guercio G; Mattioli M; Cimarosti Z; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
J Med Chem; 2009 May; 52(10):3238-47. PubMed ID: 19388677
[TBL] [Abstract][Full Text] [Related]
15. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities.
Navari RM
Curr Opin Investig Drugs; 2008 Jul; 9(7):774-85. PubMed ID: 18600583
[TBL] [Abstract][Full Text] [Related]
16. An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing.
Tonn GR; Wong SG; Wong SC; Johnson MG; Ma J; Cho R; Floren LC; Kersey K; Berry K; Marcus AP; Wang X; Van Lengerich B; Medina JC; Pearson PG; Wong BK
Drug Metab Dispos; 2009 Mar; 37(3):502-13. PubMed ID: 19088267
[TBL] [Abstract][Full Text] [Related]
17. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets.
Huskey SE; Dean BJ; Bakhtiar R; Sanchez RI; Tattersall FD; Rycroft W; Hargreaves R; Watt AP; Chicchi GG; Keohane C; Hora DF; Chiu SH
Drug Metab Dispos; 2003 Jun; 31(6):785-91. PubMed ID: 12756213
[TBL] [Abstract][Full Text] [Related]
18. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.
Prakash C; Chen W; Rossulek M; Johnson K; Zhang C; O'Connell T; Potchoiba M; Dalvie D
Drug Metab Dispos; 2008 Oct; 36(10):2064-79. PubMed ID: 18653742
[TBL] [Abstract][Full Text] [Related]
19. Application of stable isotope methodology in the evaluation of the pharmacokinetics of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride in rats.
Yamazaki S; Toth LN; Kimoto E; Bower J; Skaptason J; Romero D; Heath TG
Drug Metab Dispos; 2009 May; 37(5):937-45. PubMed ID: 19237512
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
